Abstract:Abstract Molecular diagnosis has become highly significant for patient management. Facing new challenges to generate more comprehensive data in reduced time and cost, we tested Nanopore (ONT) adaptive sampling to analyze a gene panel for germline predisposition to cancer. We tested 30 clinical germline samples carrying known alterations on BRCA1, BRCA2, PALB2 and MLH1 genes to detect large scale rearrangements (LSR) and single nucleotide variants (SNV). We used adaptive sampling to enrich the full sequence (from promoters to 3’UTR) of 152 cancer predisposition genes on ONT R10.4.1 MinION flowcells and the Q20 chemistry. The analysis was performed using the long-read bioinformatics pipeline developed by SeqOne Genomics. We observed a mean enrichment of 7.85 (3.91-9.85) and a mean coverage on target genes of 14.73X (4.71-35). In our cohort, 11 samples had LSR that were all detected with ONT sequencing. In addition to perfectly detect the locus of the LSR (starts and stops always in intronic regions), we discovered that a known MLPA amplification of exon 13 in the BRCA1 gene was in fact an amplification of both exons 12 and 13. This 2-exon duplication was also confirmed on a patient’s relative, originally diagnosed with an exon 13 duplication as well. Another LSR was a total deletion of the BRCA1 gene. ONT sequencing highlighted this complete deletion of BRCA1 was the consequence of a large deletion of almost 140 kbp carrying 5 different genes (BRCA1, IFI35, NBR2, RND2, and VAT1). ONT sequencing was also able to detect all class-5 SNVs (point mutations and small indel) present in 16 patient samples at low coverage (between 6 and 27X). We faced bioinformatics detection issues for 3 mutations located in homopolymer regions using standard pipelines. These were all confirmed correctly when visualizing the raw data. As we analyzed complete genes and more genes than with short read sequencing, we detected novel unknown variants. To check the reliability of those novel variant by ONT, we wondered whether we could confirm results obtained at a low coverage (10X) with average quality (Phread score >/= 15). For that we randomly selected 8 new variants we analyzed by Sanger sequencing, and all of these were confirmed, suggesting that variants detected with ONT, even at a 10X coverage and a Phread score higher than 15, could be considered as real variants. In conclusion, we showed that ONT adaptive sampling sequencing is suitable for the analysis of germline alterations. It improves the characterization of LSR and is able to detect SNV even at low coverage. Nevertheless, an improvement of bioinformatics detection of variants located in homopolymer regions should be considered. A larger comparison study between ONT adaptive sampling and short read sequencings should be performed on hundreds of samples to adapt international guidelines to third generation sequencing for germline diagnosis. Citation Format: Sandy Chevrier, Corentin Richard, Marie Mille, Denis Bertrand, Michael Blum, Nicolas Philippe, Romain Boidot. Nanopore adaptive sampling detects nucleotide variants and improves large scale rearrangement characterization for diagnosis of cancer predisposition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2936.

Abstract 3536: Paracell: A high throughput, deep learning-based pipeline for single-cell phenotypic profiling

Abstract 861: Improvements in variant calling sensitivity and specificity in single-cell DNA sequencing using deep learning

Abstract 2928: Solving the cancer mutation conundrum: A single cell, massively parallel approach for cancer mutation discovery, genome modelling and functional characterization

Abstract 2283: A targeted mutation calling workflow - end to end - from FASTQ to clinical report for single cells

Abstract 7325: Integration of functional data to classify BRCA1/2 missense variants: An ENIGMA project

Abstract 3012: Characterizing the functional significance of "variant of uncertain significance" of the tumour suppressor CDH1

Abstract 6218: Haplotype-resolved analysis of cancer genomes and epigenomes using Oxford Nanopore sequencing

Abstract 4884: Evaluating the utility of in silico variant annotation tools for cancer driver detection

Abstract 2934: Somatic variant workflow with HiFi sequencing provides new insights in highly challenging cancer cases

Abstract 3522: Application of large language models to nucleotide sequences for profiling signaling pathway disruptions in ovarian cancer patients

Abstract 3520: A scalable single cell RNA-seq pipeline leveraging machine learning and high-quality references for cell-type prediction

Abstract 151: an Improved Computational Pipeline for Tumor Somatic Alterations Detection

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

Abstract 2279: Cas9 based targeted nanopore sequencing helps identify structural variants in breast cancer genes

Abstract 6202: Integrating public single-cell transcriptomics and patient profiles to guide clinical development

Abstract LB234: Identifying cancer vulnerabilities associated with changes in chromatin accessibility by simultaneously profiling hundreds of cancer cell lines with ATAC-seq

Abstract 4899: Interface-guided phenotyping of coding variants in the transcription factor RUNX1

Abstract LB081: Concurrent characterization of somatic nucleotide mutations, 5mC, and 5hmC methylation in clinical research samples using a single nanopore sequencing assay

Abstract 1915: A scalable pancancer antigen target discovery platform for precision oncology

Abstract 7352: ScanCT: A tree-based machine learning model to detect single-cell genomic features associated with clinical outcomes

Abstract 2936: Nanopore adaptive sampling detects nucleotide variants and improves large scale rearrangement characterization for diagnosis of cancer predisposition